Nov 6, 2025 08:00AM
Aug 14, 2025 08:00AM
Jul 31, 2025 02:26AM
Jul 3, 2025 06:49AM
Jul 2, 2025 07:45AM
Jul 2, 2025 07:45AM
May 8, 2025 08:00AM VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Apr 28, 2025 07:10AM
Apr 25, 2025 08:02AM
Apr 25, 2025 08:00AM
Jan 6, 2025 07:30AM
Jun 5, 2024 08:00AM
May 6, 2024 08:01AM
May 6, 2024 08:00AM VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor
May 1, 2024 08:00AM
Feb 29, 2024 08:00AM
Feb 27, 2024 08:00AM
Jan 10, 2024 08:03AM
Jan 10, 2024 08:00AM
Oct 30, 2023 07:01AM
Oct 30, 2023 07:00AM VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
Mar 30, 2023 07:45AM
Mar 30, 2023 07:45AM
Mar 9, 2023 04:01PM
Feb 15, 2023 08:05AM
Feb 15, 2023 08:00AM
Jan 9, 2023 04:01PM
Nov 17, 2022 08:00AM VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
Jun 17, 2022 08:00AM
Apr 7, 2022 08:00AM
Apr 7, 2022 08:00AM
Mar 30, 2022 08:00AM
Mar 17, 2022 08:00AM
Mar 7, 2022 07:03AM
Mar 7, 2022 07:00AM VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
Jan 19, 2022 08:00AM
Jan 19, 2022 08:00AM
Jan 13, 2022 09:27AM
Jan 13, 2022 07:02AM
Jan 13, 2022 07:00AM
Nov 10, 2021 07:30AM
Nov 4, 2021 08:00AM Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
Oct 26, 2021 08:00AM
Oct 21, 2021 08:00AM
Oct 19, 2021 08:00AM
Oct 5, 2021 08:00AM
Sep 20, 2021 08:00AM
Sep 8, 2021 08:00AM
Aug 12, 2021 07:30AM VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases
Aug 12, 2021 07:00AM

322,140 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All